<b>Format of Initial Disclosure to be made by an entity identified as a Large Corporate.</b><br/><br/> <table border=''1px''><tr> <td><b>Sr. No.</b></td> <td><b>Particulars</b></td> <td><b>Details</b></td> ....
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Transgene Biotek Ltd has submitted an initial disclosure to BSE confirming that the company does not meet the criteria to be classified as a 'Large Corporate' under SEBI Circular SEBI/HO/DDHS/CIR/P/2018/144 dated November 26, 2018. Large Corporate status is determined based on thresholds related to outstanding borrowings and financial size. By confirming it does not fall under this category, the company is effectively stating its borrowings or overall financial scale is below the prescribed SEBI limits. The letter, dated October 11, 2025, is signed by Dr K Koteswara Rao, Chairman & Managing Director. This is a routine annual/initial regulatory compliance filing required under the said SEBI and BSE circulars.
This is a routine compliance disclosure with no material impact on shareholders or stock price. It simply confirms that Transgene Biotek is a smaller entity by SEBI's debt/financial thresholds, meaning it is not subject to the additional reporting and incremental borrowing requirements applicable to Large Corporates.